Norges Bank’s Stoke Therapeutics STOK Stock Holding History

Norges Bank’s Portfolio STOK Stock Details STOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-314,800	Closed	-$3.47M	–	1843
2024 Q4	$3.47M	Buy	+314,800	New	+$3.87M	﹤0.01%	1590
2024 Q2	–	Sell	-50,000	Closed	-$675K	–	1982
2024 Q1	$675K	Buy	+50,000	New	+$303K	﹤0.01%	1822
2023 Q3	–	Sell	-24,700	Closed	-$263K	–	2028
2023 Q2	$263K	Buy	+24,700	New	+$263K	﹤0.01%	1989
2023 Q1	–	Sell	-394,312	Closed	-$3.64M	–	2161
2022 Q4	$3.64M	Buy	394,312 +199,900	+103%	+$2.08M	﹤0.01%	1868
2022 Q3	$2.5M	Hold	194,412	–	–	﹤0.01%	1878
2022 Q2	$2.57M	Buy	194,412 +48,812	+34%	+$742K	﹤0.01%	1867
2022 Q1	$3.06M	Buy	+145,600	New	+$2.92M	﹤0.01%	1931
2021 Q4	–	Sell	-45,200	Closed	-$1.15M	–	2287
2021 Q3	$1.15M	Buy	+45,200	New	+$1.26M	﹤0.01%	2132
2019 Q4	–	Sell	-25,000	Closed	-$537K	–	2093
2019 Q3	$537K	Hold	25,000	–	–	﹤0.01%	2059
2019 Q2	$729K	Buy	+25,000	New	+$671K	﹤0.01%	2048

Other funds holding STOK

Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Norges Bank's STOK Position: Q1 2025 in Review

Norges Bank sold out of Stoke Therapeutics (STOK) in Q1 2025, closing a stake of 314,800 shares — an estimated $3.47M sold.

Norges Bank first reported a position in STOK in Q2 2019 and held it in 10 quarters. The position peaked at $3.64M in Q4 2022. 126 funds tracked by Wall St. Rank hold STOK as of Q1 2025.

Norges Bank reported no remaining Stoke Therapeutics position as of Q1 2025 after selling out during the quarter.
Norges Bank sold 314,800 Stoke Therapeutics shares in Q1 2025, an estimated $3.47M.
Norges Bank first reported a position in Stoke Therapeutics in Q2 2019 and held it in 10 quarters.
Norges Bank's Stoke Therapeutics position peaked at $3.64M in Q4 2022.
126 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2025.

Based on Norges Bank's 13F filing for Q1 2025, filed 13 May 2025.